Treatment of Latent Tuberculosis Infection

Initial Evaluation and Treatment

The Centers for Disease Control and Prevention (CDC) recommends that patients with a positive Interferon Gamma Release Assay (IGRA) indicating latent TB infection should be treated with short-course rifamycin-based regimens (3-4 months) after excluding active TB disease through chest radiography and clinical evaluation 1, 2
The CDC and National Tuberculosis Controllers Association strongly recommend the following preferred regimens for LTBI treatment: 3 months of once-weekly rifapentine plus isoniazid, 4 months of daily rifampin monotherapy, or 3 months of daily isoniazid plus rifampin 1, 2, 3
For patients who cannot take rifamycin-based regimens, 6 months of daily isoniazid is a strong alternative recommendation 1, 2, 3

The CDC recommends testing all HIV-infected patients for M. tuberculosis infection with either TST or IGRA upon initiation of care, and treating all HIV-infected patients with positive IGRA or TST after excluding active TB disease 4, 5, 6
HIV-infected patients who are close contacts of persons with infectious TB should be treated for LTBI regardless of TST or IGRA results, after active TB is excluded 4, 5, 6

Baseline liver function tests are recommended for patients at risk for hepatotoxicity, including those aged ≥35 years, with underlying liver disease, concurrent hepatotoxic medications, alcohol use, or HIV infection 3
Monthly clinical monitoring for symptoms of hepatotoxicity is recommended for patients on isoniazid-based regimens 3
Screen for drug-drug interactions before initiating rifamycins, as they are potent CYP450 inducers 1, 2

IGRAs perform similarly to TST at identifying individuals with latent TB infection but have less cross-reactivity with BCG vaccination 4, 5, 6
Either TST or IGRA can be used for LTBI testing in high-income and upper-middle-income countries with TB incidence <100 per 100,000 7, 8

The European Respiratory Society recommends screening all patients for TB symptoms (cough, hemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue) before testing or treating for LTBI 9
Individuals with TB symptoms or radiological abnormalities require further investigation for active TB before any LTBI treatment, as recommended by the European Respiratory Society 9

For patients who cannot tolerate rifamycin-based regimens, 9 months of isoniazid has higher efficacy (93% in completer-compliers) compared to 6 months (69%), as reported in the European Respiratory Journal 10

The European Respiratory Society recommends systematic testing and treatment of LTBI is mandatory before starting anti-TNF agents due to high TB reactivation risk 9
For children aged <5 years exposed to smear-positive TB, the European Respiratory Journal recommends initiating preventive chemotherapy with isoniazid immediately, even if tuberculin skin test is negative at screening 11
The American Academy of Pediatrics and the Centers for Disease Control and Prevention recommend isoniazid for 9 months as the only recommended regimen for children in most guidelines 12

The Infectious Diseases Society of America recommends never adding a single drug to a failing regimen, as this creates de facto monotherapy and rapidly generates resistance 12
The Centers for Disease Control and Prevention and the Infectious Diseases Society of America recommend not using rifampin in pregnant women 12
The American College of Chest Physicians and the Infectious Diseases Society of America recommend that isoniazid use in persons aged >35 years carries increased hepatotoxicity risk requiring closer monitoring 12

The American College of Physicians recommends obtaining baseline liver function tests, including AST/ALT and bilirubin, in patients with certain risk factors, such as pregnancy or within 3 months postpartum, before starting LTBI treatment 13
The Centers for Disease Control and Prevention suggests that IGRA is preferred over TST in BCG-vaccinated individuals due to less cross-reactivity 13

The Infectious Diseases Society of America recommends monthly clinical monitoring to assess adherence, review symptoms of adverse drug reactions, and check for hepatotoxicity signs, although routine laboratory monitoring is not indicated for low-risk patients 13

All healthcare workers with a positive IGRA result should undergo chest radiography and a systematic symptom screen to exclude active tuberculosis before initiating treatment for latent infection. 14
Chest radiographs are obtained to identify air‑space opacities, pleural effusions, cavitary lesions, or other abnormalities that may indicate active disease. 14
If radiographic abnormalities or TB‑compatible symptoms are present, sputum specimens must be collected and the individual managed as a potential active TB case. 14

In Indian healthcare workers, IGRA conversion rates of roughly 12 % and reversion rates of about 24 % have been observed during serial testing, with many changes occurring near the assay cut‑off values. 15
These IGRA conversion and reversion rates are 6–9 times higher than those seen with the tuberculin skin test, indicating that many may represent false conversions rather than true new infections. 15

Clinicians must not interpret IGRA results quantitatively beyond the FDA‑approved positive/negative cut‑points, as optimal thresholds for clinical decision‑making remain controversial. 14